• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Genentech ’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

    FDA Grants Genentech ’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

  2. Genentech ’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

    Genentech ’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening

  3. FDA Grants Genentech ’s Avastin Priority Review for Certain Types of Cervical Cancer

    FDA Grants Genentech ’s Avastin Priority Review for Certain Types of Cervical Cancer

  4. Genentech to Buy Seragon Pharmaceuticals for up to $1.725 Billion

    Genentech to Buy Seragon Pharmaceuticals for up to $1.725 Billion

  5. Genentech to Buy Seragon Pharma For up to $1.725 Billion

    Genentech to Buy Seragon Pharma For up to $1.725 Billion

  6. Roche Not Interested in Large Acquisitions, Says CEO -- Report

    Roche Not Interested in Large Acquisitions, Says CEO -- Report

  7. Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma

  8. Roche to buy Seragon for up to $1.725 billion

    Roche to buy Seragon for up to $1.725 billion

  9. EUROPE MARKETS: Alcatel, Roche Up In Europe, But Orange Shares Sour

    EUROPE MARKETS: Alcatel, Roche Up In Europe, But Orange Shares Sour

  10. UPDATE: Alcatel, Roche up in Europe, but Orange shares sour

    UPDATE: Alcatel, Roche up in Europe, but Orange shares sour

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.